Catalyst Pharmaceuticals (CPRX) Tops Q2 EPS by 33c, Beats on Revenue; Offers FY24 Revenue Guidance
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.49 --0%
Financial Fact:
General and administrative: 1.42M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Financial Fact:
General and administrative: 1.42M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q2 EPS of $0.56, $0.33 better than the analyst estimate of $0.23. Revenue for the quarter came in at $122.7 million versus the consensus estimate of $111.77 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2024 revenue of $455-475 million, versus the consensus of $462.4 million.
For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. and Denmark close in on a Greenland deal - Reuters
- Teva shares Phase 3 data on once-monthly schizophrenia injection
- Empire Petroleum (EP) files $150M mixed shelf
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
